Diabetes, Vol 28, Issue 1 41-51, Copyright © 1979 by American Diabetes Association

ARTICLES

Pharmacogenetics of tolbutamide metabolism in humans

J Scott and PL Poffenbarger

This study was designed to focus on the genetic control of tolbutamide dispositon in humans and to provide insight into the potential for high accrued blood levels in individuals receiving fixed dosage regimens. Tolbutamide was administered intravenously to 42 nondiabetic subjects, eight of their relatives, and to five sets of twins. A ninefold variation in the rate of tolbutamide disappearance from plasms (Kd) was found. This variation was characterized by a trimodal frequency distribution, suggestive of monogenic inheritance and consistent with pedigree analysis, indicating autosomal transmission of rapid and slow inactivation of tolbutamide. A heritability value of 0.995 for Kd indicated little influence of environmental factors on variation of this rate. Interindividual differences in the binding of 35S-tolbutamide to serum proteins were also assessed. No correlation was found between tolbutamide serum protein binding affinity and Kd. Analysis of the metabolites of tolbutamide in urine samples provided evidence for the microsomal oxidation of the drug to hydroxytolbutamide as the primary site of genetic control. In conclusion, this study provides evidence for monogenic control of tolbutamide metabolism in man. The results suggest that fixed dosage regimens of this drug, as were prescribed in the controversial University Group Diabetes Program study, might lead to higher accrued blood levels in slow inactivators.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]

				P. Boileau, C. Wolfrum, D. Q. Shih, T.-A. Yang, A. W. Wolkoff, and M. Stoffel Decreased Glibenclamide Uptake in Hepatocytes of Hepatocyte Nuclear Factor-1{alpha}-Deficient Mice: A Mechanism for Hypersensitivity to Sulfonylurea Therapy in Patients With Maturity-Onset Diabetes of the Young, Type 3 (MODY3) Diabetes, December 1, 2002; 51(90003): S343 - 348. [Abstract] [Full Text] [PDF]

				K. Komatsu, K. Ito, Y. Nakajima, S.-i. Kanamitsu, S. Imaoka, Y. Funae, C. E. Green, C. A. Tyson, N. Shimada, and Y. Sugiyama Prediction of in Vivo Drug-Drug Interactions between Tolbutamide and Various Sulfonamides in Humans Based on in Vitro Experiments Drug Metab. Dispos., April 1, 2000; 28(4): 475 - 481. [Abstract] [Full Text]

				M. R. Wester, J. M. Lasker, E. F. Johnson, and J. L. Raucy CYP2C19 Participates in Tolbutamide Hydroxylation by Human Liver Microsomes Drug Metab. Dispos., March 1, 2000; 28(3): 354 - 359. [Abstract] [Full Text] [PDF]

				R. S. Obach Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes Drug Metab. Dispos., November 1, 1999; 27(11): 1350 - 1359. [Abstract] [Full Text]

				Y.W. F. Lam and M. V. Marshall Genetically Determined Polymorphisms in Drug Metabolism Journal of Pharmacy Practice, January 1, 1992; 5(6): 317 - 336. [Abstract] [PDF]